Építés alatt – nem éles oldal
Belépés
Résztvevőt keresFázis nélkül

Persistent Villous Atrophy in Celiac Disease Patients Following an Intentionally Strict Gluten-free Diet

A legfontosabb adatok

Ki végzi
Hospital Mutua de Terrassa
Hol
Spanyolország1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Résztvevők
80 fő, tervezett
Kezdés
2022. jan. 1.
Várható befejezés
2027. jan. 1.
A vizsgálat típusa
Megfigyeléses
A vizsgált kezelések
  • Ultra-strict gluten-free diet
A regiszteradat frissítve
2024. július 19.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with celiac disease who have been on a gluten-free diet for at least 2 years. It studies why the small intestine lining stays damaged and tests an ultra-strict gluten-free diet.

Életkor
20 Years to 80 Years. Celiac disease must have been diagnosed at age 18 years or more.
Nem
All sexes can join.
A betegség stádiuma
Celiac disease diagnosed with villous atrophy (flattened lining of the small intestine). Symptoms and blood tests must have improved on a gluten-free diet.
Korábbi kezelés
A gluten-free diet for at least 2 years, followed closely.
Biomarker vagy leletérték
Positive celiac blood tests at diagnosis. At recruitment, anti-transglutaminase (tTG2) IgA antibodies must be negative or low (<2 times the normal value).

A részvétel fő kizáró okai

  • Refractory celiac disease type 1 or type 2, or other bowel diseases such as inflammatory bowel disease or microscopic colitis
  • Needing corticosteroids or immunosuppressants
  • Surgery or disease that favours bacterial overgrowth in the small intestine
  • Pregnancy or breastfeeding
  • Chronic lung, heart or kidney disease, liver cirrhosis, alcoholism, drug addiction, schizophrenia-type illness, other psychoses or bipolar disorder

A regiszter feltételei, szó szerint

Mind a 13 feltétel megnézéseKevesebb

Ki vehet részt

  • Age at diagnosis 18 years or more
  • Diagnosis of CD with villous atrophy, positive serology and clinical and serological response to GFD
  • To be in a GFD for at least 2 years, with good adherence to it
  • Negative or positive anti-transglutaminase (tTG2) IgA antibodies at low titers (<2 times the normal value) at recruitment
  • Written informed consent

Ki nem vehet részt

  • Need for treatment with corticosteroids or immunosuppressants
  • Alcoholism or drug addiction
  • Other associated intestinal diseases (inflammatory bowel disease, microscopic colitis, other types of enteropathies)
  • Surgeries or other diseases predisposing to bacterial overgrowth in the small intestine
  • Associated chronic diseases (lung, heart, kidney, liver cirrhosis)
  • Schizophrenia-type psychiatric diseases, other psychoses, bipolar
  • Refractory CD (RCD) type 2 and type 1
  • Pregnancy, lactation

A fő feltételek kérdésként

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 20 és 80 év között vagy?

Ez a vizsgálat jelenleg itt érhető el: Spanyolország.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Celiac disease (CD) is an immune-mediated disease characterized by small intestinal inflammation from gluten ingestion, a group of proteins present in various cereals, including wheat, rye, barley, spelt, and kamut. CD is the most common chronic gastrointestinal disease and one of the most common autoimmune disorders, estimated to affect 0.4-1.7% of the general population. Currently, a strict lifelong gluten-free diet (GFD) is the only available treatment to avoid the inappropriate inflammatory response and prevent the shortening of the villi lining the small intestine (villous atrophy). However, a significant proportion of CD patients, ranging from 4% to 79%, show persistent villous atrophy despite following an intentional GFD. The causative factors and the clinical consequences of persistent villous atrophy in CD patients are not well known yet but might resemble untreated CD long-term complications.

A teljes eredeti leírásKevesebb

Interestingly, in the precedent study (CADER) persistent villous atrophy was found to be more present in patients diagnosed at an older age (65% of CD patients diagnosed after 30 years of age) than in younger patients. Moreover, unintentional exposure to gluten was found in 70% of the cases. The causative factors of this hypersensitivity to small amounts of gluten present in older patients are unknown. The intestinal microbiota and age-related epigenetic changes may help maintaining the dysregulation of the immune response, causing older patients to be hypersensitive to small amounts of gluten.

The aim of this study (CADER2) is to identify the immunological and clinical consequences of persistent villous atrophy in CD and study whether changes in the intestinal microbiome and age-related epigenetic modifications may contribute to it. Last, the investigators want to assess if an ultra-strict GFD can be a viable and effective alternative to treat this subset of CD patients. In order to achieve these objectives, the study includes 2 phases: 1) Cross-sectional study to assess the causes and the clinical consequences of persistent villous atrophy in CD patients; and 2) Longitudinal study to evaluate the potential therapeutic effect of an ultra-strict GFD on persistent villous atrophy and its subtle clinical manifestations.

The investigators hypothesize that persistent villous atrophy in CD patients despite an intentional GFD is associated with chronic low-grade inflammation and increased circulating cytokines in blood, potentially leading to cognitive deficits, fatigue, anxiety, depression, malnutrition, sarcopenia and osteoporosis. The intestinal microbiota and age-related epigenetic changes may help to maintain the dysregulation of the immune response, causing patients to be hypersensitive to small amounts of gluten. This subset of CD patient could highly benefit from an ultra-strict GFD.

To date, six centers have been recruited: Hospital Universitari Mutua Terrassa (Barcelona), Hospital Clínico San Carlos (Madrid), Hospital Fundación Jiménez Díaz (Madrid), Hospital Universitario de La Princesa (Madrid), Hospital Universitario Ramón y Cajal (Madrid) and Hospital Universitario Virgen Macarena (Sevilla). Digestive, endocrine, nutritional and clinical psychology experts will be involved in the monitoring of the patients. Microbiome analysis will be performed at the Genomics Unit, Microbiota Laboratory (LABMIC) of the IdISSC (Madrid). The methylation studies (age-related epigenetic modifications) will be hired externally.

Overall, the results of this study (CADER2) may help identify new therapeutic strategies as well as improve the management of chronicity and care of CD patients who do not respond to the current treatment. Furthermore, it will contribute to a deeper understanding of the pathophysiological relationships between diet, microbiome, genetics and immunology in CD.

A vizsgálat csoportja

  • Celiac Disease patients

    Kezelés: Ultra-strict gluten-free diet

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Study of the Causes and Consequences of Persistent Villous Atrophy Despite an Intentionally Strict Gluten-free Diet in Celiac Disease Patients - Effect of an Ultra-strict Gluten-free Diet on Persistent Villous Atrophy
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Kérdések a feltételekről
Forrás: NCT06500754: ki vehet részt
A regiszteradat frissítve
2024. július 19.
Építés alatt, nem éles – Persistent Villous Atrophy in Celiac Disease Patients Following an Intentionally Strict Gluten-free Diet (NCT06500754) – Frontlight Research